Advances in Chemotherapy for Metastatic Breast Cancer

Sheng He

2002-01-01

Abstract:In recent years,lots of new drugs treating breast cancer have been developed,and a great deal of clinical study has been carried out.The advances in cytotoxic chemotherapy and ongoing efforts to develop novel agents for metastatic breast cancer are reviewed in this paper.

What problem does this paper attempt to address?

Recent Advances in Treatment of Metastatic Breast Cancer and Drug Research

Zhan-hong CHEN,Xiao-jia WANG

DOI: https://doi.org/10.3969/j.issn.1672-3384.2014.02.001

2014-01-01

Abstract:Objective:To review the recent advances in the treatment of advanced breast cancer and drug research. Methods: We collected the latest research related to the treatment of advanced breast cancer and drugs, then give the analysis and summary. Results and conclusion: Metastatic breast cancer currently has no cure, fortunately,a new generation of antitumor-drug were available in clinical application, such as taxanes, trastuzumab and the third generation of aromatase inhibitors, then the survival and quality of life of patients was signiifcantly improved . Clinical practice has proved that metastatic breast cancer gradually evolved into a chronic disease. In recent years, some new mechanisms antitumor drugs such as Pertuzumab,T-DM1,Fulvestrant and Everolimus, etc, wil change the strategy of metastatic breast cancer.
Advances in Antitumor Drugs

He Wang,Xiaoyong Li,Pei-Hsin Cheng,Maria Luisa Bondı̀,Biyun Wang,Ymera Pignochino

2016-01-01

Abstract:Chemotherapy is a category of cancer treatment that uses chemical substances, especially one or more antitumor drugs that are given as part of a standardized chemotherapy regimen. Chemotherapy may be given with a curative intent which almost always involves combinations of antitumor drugs, or it may aim to prolong life or to reduce symptoms. By common usage, the term chemotherapy has come to connote the use of rather non-specific intracellular poisons, especially related to inhibiting the process of cell division known as mitosis, and generally excludes agents that more selectively block extracellular growth signals. Importantly, the use of antitumor drugs constitutes “systemic therapy” for cancer in that they are introduced into the blood stream and are therefore in principle able to address cancer at any anatomic location in the body. In the present book, twelve typical literatures about antitumor drugs published on international authoritative journals were selected to introduce the worldwide newest progress, which contains reviews or original researches on medical science, oncology, chemotherapy, ect. We hope this book can demonstrate advances in antitumor drugs as well as give references to the researchers, students and other related people.
Advancements in clinical aspects of targeted therapy and immunotherapy in breast cancer

Feng Ye,Saikat Dewanjee,Yuehua Li,Niraj Kumar Jha,Zhe-Sheng Chen,Ankush Kumar,Vishakha,Tapan Behl,Saurabh Kumar Jha,Hailin Tang

DOI: https://doi.org/10.1186/s12943-023-01805-y

IF: 37.3

2023-07-07

Molecular Cancer

Abstract:Breast cancer is the second leading cause of death for women worldwide. The heterogeneity of this disease presents a big challenge in its therapeutic management. However, recent advances in molecular biology and immunology enable to develop highly targeted therapies for many forms of breast cancer. The primary objective of targeted therapy is to inhibit a specific target/molecule that supports tumor progression. Ak strain transforming, cyclin-dependent kinases, poly (ADP-ribose) polymerase, and different growth factors have emerged as potential therapeutic targets for specific breast cancer subtypes. Many targeted drugs are currently undergoing clinical trials, and some have already received the FDA approval as monotherapy or in combination with other drugs for the treatment of different forms of breast cancer. However, the targeted drugs have yet to achieve therapeutic promise against triple-negative breast cancer (TNBC). In this aspect, immune therapy has come up as a promising therapeutic approach specifically for TNBC patients. Different immunotherapeutic modalities including immune-checkpoint blockade, vaccination, and adoptive cell transfer have been extensively studied in the clinical setting of breast cancer, especially in TNBC patients. The FDA has already approved some immune-checkpoint blockers in combination with chemotherapeutic drugs to treat TNBC and several trials are ongoing. This review provides an overview of clinical developments and recent advancements in targeted therapies and immunotherapies for breast cancer treatment. The successes, challenges, and prospects were critically discussed to portray their profound prospects.

oncology,biochemistry & molecular biology
New Advances in the Research of Resistance to Neoadjuvant Chemotherapy in Breast Cancer

Junsha An,Cheng Peng,Hailin Tang,Xiuxiu Liu,Fu Peng

DOI: https://doi.org/10.3390/ijms22179644

IF: 5.6

2021-09-06

International Journal of Molecular Sciences

Abstract:Breast cancer has an extremely high incidence in women, and its morbidity and mortality rank first among female tumors. With the increasing development of medicine today, the clinical application of neoadjuvant chemotherapy has brought new hope to the treatment of breast cancer. Although the efficacy of neoadjuvant chemotherapy has been confirmed, drug resistance is one of the main reasons for its treatment failure, contributing to the difficulty in the treatment of breast cancer. This article focuses on multiple mechanisms of action and expounds a series of recent research advances that mediate drug resistance in breast cancer cells. Drug metabolizing enzymes can mediate a catalytic reaction to inactivate chemotherapeutic drugs and develop drug resistance. The drug efflux system can reduce the drug concentration in breast cancer cells. The combination of glutathione detoxification system and platinum drugs can cause breast cancer cells to be insensitive to drugs. Changes in drug targets have led to poorer efficacy of HER2 receptor inhibitors. Moreover, autophagy, epithelial–mesenchymal transition, and tumor microenvironment can all contribute to the development of resistance in breast cancer cells. Based on the relevant research on the existing drug resistance mechanism, the current treatment plan for reversing the resistance of breast cancer to neoadjuvant chemotherapy is explored, and the potential drug targets are analyzed, aiming to provide a new idea and strategy to reverse the resistance of neoadjuvant chemotherapy drugs in breast cancer.

biochemistry & molecular biology,chemistry, multidisciplinary
Recent Advances in the Treatment of Breast Cancer

Christy W. S. Tong,Mingxia Wu,William C. S. Cho,Kenneth K. W. To

DOI: https://doi.org/10.3389/fonc.2018.00227

IF: 4.7

2018-06-14

Frontiers in Oncology

Abstract:Breast cancer (BC) is the most common malignancy in women. It is classified into a few major molecular subtypes according to hormone and growth factor receptor expression. Over the past few years, substantial advances have been made in the discovery of new drugs for treating BC. Improved understanding of the biologic heterogeneity of BC has allowed the development of more effective and individualized approach to treatment. In this review, we provide an update about the current treatment strategy and discuss the various emerging novel therapies for the major molecular subtypes of BC. A brief account of the clinical development of inhibitors of poly(ADP-ribose) polymerase, cyclin-dependent kinases 4 and 6, phosphatidylinositol 3-kinase/protein kinase B/mammalian target of rapamycin pathway, histone deacetylation, multi-targeting tyrosine kinases, and immune checkpoints for personalized treatment of BC is included. However, no targeted drug has been approved for the most aggressive subtype-triple negative breast cancer (TNBC). Thus, we discuss the heterogeneity of TNBC and how molecular subtyping of TNBC may help drug discovery for this deadly disease. The emergence of drug resistance also poses threat to the successful development of targeted therapy in various molecular subtypes of BC. New clinical trials should incorporate advanced methods to identify changes induced by drug treatment, which may be associated with the upregulation of compensatory signaling pathways in drug resistant cancer cells.

oncology
Recent advances in breast cancer and the future directions of research

Yawei Shi,Shenming Wang

DOI: https://doi.org/10.3760/cma.j.issn.1001-9030.2016.04.001

2016-01-01

Abstract:2015 is an important year for breast cancer fundamental research.Scientists have made great achievements in several fields,such as carcinogenesis,metastasis,medical resistance,chemotherapy,immunotherapy,genomics and biochemical technique,which laid a firm foundation for individual accurate therapy.This article will summarize recent advances in breast cancer,and look for the future directions of research.
Latest Advances in Breast Cancer Treatment Reported in 2018 Annual Conference of American Society of Clinical Oncology

Shao Zhimin,Liu Yin

DOI: https://doi.org/10.3877/cma.j.issn.1674-0807.2018.06.002

2018-01-01

Abstract:The annual conference of American Society of Clinical Oncology (ASCO) in 2018 showed us the latest advances in chemotherapy, endocrine therapy and immunotherapy for breast cancer. In the field of chemotherapy, there is still an attempt to select people for exemption from chemotherapy or to try to relieve the drug burden. In the development of new compound and in the combination of chemotherapy and targeted therapy, the researchers are looking for more precise and targeted regimens. With regards to endocrine therapy, traditional endocrine drug combined with targeted therapy is still a hot spot. Immunotherapy has been proved effective in metastatic breast cancer, and now researchers are trying to investigate the clinical value of immunotherapy in early breast cancer. Key words: Breast neoplasms; Chemotherapy; Endocrine therapy; Targeted therapy; Immunotherapy
Advances in Chemotherapy and Targeted Therapies in Endometrial Cancer

Setsuko K Chambers

DOI: https://doi.org/10.3390/cancers14205020

2022-10-14

Abstract:Endometrial cancer is now recognized to be several diseases with differing biology and responses to treatment. Improved molecular characterization has furthered the development and testing of targeted therapies in the different cohorts of endometrial cancer. Lessons are being learned from other cancers that share similar molecular typing, and hence, potentially similar tumor behavior. This commentary serves as a broad overview of the types of advances to which our patients now have access.
Metastatic breast cancer: understanding current management options

K McGinn,J Moore

Abstract:Purpose/objectives: To review the standard treatment options for metastatic breast cancer, present recently approved chemotherapeutic and hormonal approaches, and describe novel biologic therapies, particularly the use of monoclonal antibodies. Data sources: Published articles, abstracts, and conference proceedings. Data synthesis: Standard treatment options available to women with metastatic breast cancer include surgery, radiation therapy, hormonal therapy, chemotherapy, and palliative approaches. New chemotherapeutic approaches for the management of metastatic breast cancer include the recently approved agents paclitaxel, docetaxel, and capecitabine. New hormonal agents such as toremifene, letrozole, and exemestane also have been approved. Finally, an agent from a new class of agents--biologic response modifiers (BRMs)--now. Is available. Trastuzumab, a monoclonal antibody (one class of BRMs), is a new and promising approach available to a subpopulation of women with metastatic breast cancer. Conclusion: Although standard treatment options for the management of metastatic breast cancer may prolong survival for some, they have not resulted in a cure for the majority of women. Recent advances in the understanding of cancer cellular biology have led to newer approaches such as monoclonal antibodies and other BRMs that may offer hope of extended survival and improved quality of life for certain women. This field is growing quickly, and new targets for breast cancer therapy are being studied. Implications for nursing practice: Nurses who become familiar with newer treatment options available for the management of metastatic breast cancer, including new chemotherapeutic and hormonal approaches and monoclonal antibody therapy, are better able to provide information and support for their patients. Clinicians must understand the criteria for patient selection for newer agents, particularly trastuzumab. In addition, recognizing adverse effects and knowing the management strategies for treatment-related toxicities help to ensure positive patient outcomes.
Current Advances in the Study of Anticancer Drugs

LIU Feng,Wei Xin-ting,Wang Dong-dong,SUN De-zhi,LI Li-Wei

DOI: https://doi.org/10.3969/j.issn.1672-6634.2006.01.013

2006-01-01

Abstract:Cancer is one of the serious diseases that threatens human health.Recently,great progress has been made in the research of anticancer medicines.A review is given here,it covers the metal anticancer agent,the medicine picked up from natural plants,targeted drug delivery systems,genetic engineering medicines,medical nanoparticles and the relationship between cancer and trace elements.
Advances in medical treatment of breast cancer in 2022

Jingtong Zhai,Yun Wu,Fei Ma,Virginia Kaklamani,Binghe Xu

DOI: https://doi.org/10.1002/cai2.46

2023-02-23

Cancer Innovation

Abstract:This article summarizes the annual progress of breast cancer chemotherapy, targeted therapy, endocrine therapy and immunotherapy in 2022, providing valuable information for future research to better guide individualized treatment of breast cancer, thereby improving the prognosis and quality of life of breast cancer patients. Breast cancer has replaced lung cancer as the most common malignancy worldwide. The 5‐year survival rate of breast cancer has reached 90%. Systemic treatment of breast cancer has developed into a mature system including chemotherapy, targeted therapy, endocrine therapy and immunotherapy. This article summarizes the annual progress of breast cancer chemotherapy, targeted therapy, endocrine therapy and immunotherapy in 2022, providing valuable information for future research to better guide individualized treatment of breast cancer, thereby improving the prognosis and quality of life of breast cancer patients.
Breast Cancer: an Overview of Current Therapeutic Strategies, Challenge, and Perspectives

Jun Wang,San -Gang Wu

DOI: https://doi.org/10.2147/bctt.s432526

2023-01-01

Abstract:Breast cancer is the most commonly diagnosed cancer and the leading cause of death among female patients, which seriously threatens the health of women in the whole world. The treatments of breast cancer require the cooperation of a multidisciplinary setting and taking tumor load and molecular makers into account. For early breast cancer, breast-conserving surgery with radiotherapy or mastectomy alone remains the standard management, and the administration of adjuvant systemic therapy is decided by the status of lymph nodes, hormone receptors, and human epidermal growth factor receptor-2. For metastatic breast cancer, the goal of treatments is to prolong survival and maintain quality of life. This review will present the current advances and controversies of surgery, chemotherapy, radiotherapy, endocrine therapy, targeted therapy, immunotherapy, gene therapy, and other innovative treatment strategies in early-stage and metastatic breast cancer.
Recent advances in antibody-drug conjugates for breast cancer treatment.

Shanshan Deng,Zongtao Lin,Wei Li

DOI: https://doi.org/10.2174/0929867324666170530092350

IF: 4.74

2017-01-01

Current Medicinal Chemistry

Abstract:Breast cancer is the most common cancer in women, with roughly half a million deaths per year worldwide. Among various approaches for breast cancer treatment, chemotherapy is predominantly used for patients at stages II-IV, and monoclonal antibody (mAb) therapy is used for patients with human epidermal growth factor receptor 2 (HER2) overexpression. Integrating the tumor specificity provided by unique mAbs and cytotoxicity of small molecule drugs, antibody-drug conjugates (ADCs) are a series of smart chemotherapeutics that have recently shown great promise in treating a number of cancer types. ADCs are designed to selectively attack and kill cancer cells with minimal toxicity to normal tissues. Ado-Trastuzumab emtansine (T-DM1) was the first and only ADC approved by the US Food and Drug Administration for HER2-positive breast cancer. Following the success of T-DM1, many novel ADCs have been developed, and their anticancer efficacies are currently undergoing preclinical or clinical investigation. The development of ADCs is a rapidly progressing field, and this review aims to summarize the most recent advances in ADCs targeting breast cancer over the past five years (2011-2016). The review highlights compositions and mechanisms of action of these newly developed ADCs and discusses current challenges and future directions of developing new ADCs for improved treatment of breast cancer.
Research Advancement in the 41st San Antonio Breast Cancer Symposium

Zhang Yi

DOI: https://doi.org/10.3877/cma.j.issn.1674-0807.2019.03.001

2019-01-01

Abstract:The 41st San Antonio Breast Cancer Symposium was held in San Antonio, Texas, USA on December 4-8, 2018. In this article, we reviewed the key advancement in breast cancer surgery, chemotherapy, targeted therapy, immunotherapy and endocrine therapy reported in this symposium, in order to provide references for clinicians in the treatment and research of breast cancer. The 10-year follow-up data of the EORTC AMAROS study suggested that axillary radiotherapy was a safe and feasible alternative to axillary lymph node dissection for primary breast cancer patients with positive axillary lymph nodes confirmed by sentinel lymph node biopsy. The result of the phase 3 GEICAM/CIBOMA study showed that in early triple negative breast cancer patients, capecitabine administration after surgery and standard chemotherapy did not significantly improve the patients’ survival. The meta-analysis conducted by researchers in Harvard University suggested that the patients who achieve pCR after neoadjuvant chemotherapy could be exempted from conventional adjuvant chemotherapy, with no obvious effect on patients’ survival. The multi-center PEONY study conducted by Professor Shao Zhimin in China showed that for neoadjuvant therapy of early or locally advanced HER-2 positive breast cancer patients in Asia, the overall postoperative pCR rate of double-target group (pertuzumab monoclonal antibody + trastuzumab monoclonal antibody + docetaxel) was significantly higher than that of single-target group (trastuzumab monoclonal antibody + docetaxel). The KATHERINE study showed that the trastuzumab monoclonal antibody combined with maitansine conjugate was feasible in the adjuvant treatment of HER-2 positive early breast cancer. An exploratory analysis to evaluate the efficacy of immuno-biomarker subgroups in the IMpassion 130 study showed that the patients with programmed death ligand 1 positive in immunocytes significantly benefited from the treatment of atezolizumab monoclonal antibody + albumin paclitaxel. The PALLET study showed that in postmenopausal early breast cancer patients with ER positive and HER-2 negative, the neoadjuvant endocrine therapy of letrozole combined with CDK4/6 inhibitors significantly increased the inhibition rate of Ki67, but did not improve the clinical response rate. The 10-year clinical data of the AERAS study showed that the patients significantly benefited from the adjuvant endocrine therapy if the use of anastrozole was extended to 10 years. The meta-analysis of EBCTCG showed that prolonged endocrine therapy significantly reduced the overall risk of recurrence in hormone receptor-positive postmenopausal breast cancer. The TAM-01 study suggested that low-dose administration of tamoxifen could reduce the toxicity and improve the efficacy in patients with breast intraductal neoplasms. The clinicians should actively promote the clinical research of new drugs and the exploratory analysis of predictive biomarkers, take the advantages of domestic researches and learn advanced techniques and concepts overseas in order to benefit most of breast cancer patients. Key words: Breast neoplasms; Endocrine therapy; Triple negative breast cancer; Neoadjuvant therapy; Immunotherapy
Updates in Treatment of HER2-positive Metastatic Breast Cancer

Alzira R. M. Avelino,Soumya Pulipati,Kevin Jamouss,Prarthna V. Bhardwaj

DOI: https://doi.org/10.1007/s11864-024-01277-2

2024-11-10

Current Treatment Options in Oncology

Abstract:The therapeutic landscape for HER2-positive metastatic breast cancer has exploded in the last two decades following the initial advent of trastuzumab, a monoclonal antibody. While the first line treatment has remained a combination of dual HER2 blockade with taxane chemotherapy, we now have several exciting options in the second line and beyond. The introduction of antibody-drug conjugates, in specific trastuzumab deruxtecan, has resulted in the best progression-free survival among patients with this subtype of breast cancer. Given the excellent outcomes of these drugs, clinical trials are now evaluating the role of ADCs in the front-line setting in previously untreated patients. In addition, there are also clinical trials evaluating the role of other targets in patients with HER2-positive cancers, including PI3KCA mutations, PD-L1 and CDK4/6. Given the predilection for brain metastases in this population, there is enthusiasm to identify the optimal combination of effective treatments. Tucatinib, capecitabine, and trastuzumab combination represent one such promising strategy. With the increasing longevity of these patients, important clinical questions include optimal treatment sequencing, the role of de-escalation of treatment in excellent responders, and the associated financial toxicity. Despite the aggressive nature of this subtype of breast cancer, the outcomes continue to improve for these patients with the evolving treatments.

oncology
A New Strategy for the Treatment of Heavily Pretreated Metastatic Breast Cancer: A Case Report and Review of the Literature

Tingting Ge,Xun Pan,Ximeng Zuo,Xiao-guang Shi,Yukun Wang,Ping Sun,Xiang Gao,Feng Xue,Shuang Gao,Tangshun Wang

DOI: https://doi.org/10.1097/md.0000000000036297

IF: 1.6

2023-01-01

Medicine

Abstract:Breast cancer is one of the most common type of cancers worldwide and remains a critical health issue. Although there are numerous treatment options for advanced metastatic breast cancer, the results are not satisfactory, particularly for triple-negative breast cancer. New treatment modalities need to be explored.We present the case of a breast cancer patient with multiple metastases who achieved a good response and tolerance to the combination treatment of utidelone plus capecitabine. After being treated with 10 cycles of combined treatment, the patient is now in a good general condition with a progression-free survival time of 10 months.To our knowledge, this is the first report of utidelone plus capecitabine successfully treating a patient with heavily pretreated metastatic breast cancer. This combined treatment offers a new option for patients with multi-drug resistant breast cancer.
Recent Perspectives of Management of Breast Cancer Metastasis - an Update.

Qingzhong Tian,Yun Wang,Hao Guo,Guangwei Xie,Jin Li,Minkang Zhang,Qianjin Zhang,Qingliang Meng

2017-01-01

Abstract:Breast cancer is the leading cause of cancer related deaths in women and one of the most common cancers globally. The major obstacle in the management of breast cancer, especially at advanced stages, is metastasis. Metastasis in the advanced stages of breast cancer could decrease survival to approximately 5 years. The reasons could include lack of targeted receptors or chemotherapeutic agents for the management of advanced-stage breast cancer metastasis. The new emerging avenues for the management of this deadly pathological state include local manipulations like radiofrequency ablation (RFA), microwave thermotherapy, cryosurgery (cryotherapy), chemoembolization, radioembolization, breast surgery, or metastasectomy. Few single-institution reports showed improved survival in selected patients like those with oligometastatic stage IV breast cancer. The present review article focused on these emerging new multimodality treatment approaches for a possible efficient management.
Breast Cancer: Recent Advances in Molecular Approaches

Yanjie Shen,Deyu Zhang,Qinong Ye

DOI: https://doi.org/10.1016/j.scib.2022.03.003

IF: 18.9

2022-01-01

Science Bulletin

Abstract:Breast cancer is one of the most prevalent cancers worldwide and a major cause of cancer-related mortality in women.Although recent breast cancer therapies,including surgery,radiotherapy,chemotherapy,targeted therapy,and endocrine therapy,have sub-stantially improved patient survival,the cure rate is still low.Understanding the molecular mechanisms underlying breast can-cer development,progression,and therapy resistance may provide potential targets for developing novel treatments.Research has focused on advanced molecular technologies such as single-cell sequencing,clustered regularly interspaced short palindromic repeats(CRISPR),and CRISPR-associated(Cas)systems to explain these mechanisms.Here,we focus on the application of these tech-nologies in breast cancer research.
Chemotherapy strategy for metastatic breast cancer

Xiao Lin,Qian Hu,Herui Yao

DOI: https://doi.org/10.3877/cma.j.issn.1674-0785.2015.06.019

2015-01-01

Abstract:Breast cancer is the most common cancer in women, which continues to be a major cause of morbidity and mortality among women throughout the world, an estimated 500 000 women died of this disease per year in worldwide. The therapeutic goal of metastatic breast cancer is to control the disease, relieve symptoms, prolong progression free survival, improve the quality of life of patients and reduce treatment-related toxicity. This article recommend the chemotherapy indication of metastatic breast cancer, the effects of different chemotherapy regimens, and the application for subsequent maintenance chemotherpy scheme in patients with metastatic disease.
Advances of nanomedicines in breast cancer metastasis treatment targeting different metastatic stages

Wenqi Yu,Chuan Hu,Huile Gao

DOI: https://doi.org/10.1016/j.addr.2021.113909

IF: 16.1

2021-01-01

Advanced Drug Delivery Reviews

Abstract:Breast cancer is the most common tumor in women, and the metastasis further increases the malignancy with extremely high mortality. However, there is almost no effective method in the clinic to completely inhibit breast cancer metastasis due to the dynamic multistep process with complex pathways and scattered occurring site. Nowadays, nanomedicines have been evidenced with great potential in treating cancer metastasis. In this review, we summarize the latest research advances of nanomedicines in anti-metastasis treatment. Strategies are categorized according to the metastasis dynamics, including primary tumor, circulating tumor cells, pre-metastatic niches and secondary tumor. In each different stage of metastasis process, nanomedicines are designed specifically with different functions. At the end of the review, we give our perspectives on current limitations and future directions in anti-metastasis therapy. We expect the review provides comprehensive understandings of anti-metastasis therapy for breast can-cer, and boosts the clinical translation in the future to improve women's health. (c) 2021 Elsevier B.V. All rights reserved.

Advances in Chemotherapy for Metastatic Breast Cancer

Recent Advances in Treatment of Metastatic Breast Cancer and Drug Research

Advances in Antitumor Drugs

Advancements in clinical aspects of targeted therapy and immunotherapy in breast cancer

New Advances in the Research of Resistance to Neoadjuvant Chemotherapy in Breast Cancer

Recent Advances in the Treatment of Breast Cancer

Recent advances in breast cancer and the future directions of research

Latest Advances in Breast Cancer Treatment Reported in 2018 Annual Conference of American Society of Clinical Oncology

Advances in Chemotherapy and Targeted Therapies in Endometrial Cancer

Metastatic breast cancer: understanding current management options

Current Advances in the Study of Anticancer Drugs

Advances in medical treatment of breast cancer in 2022

Breast Cancer: an Overview of Current Therapeutic Strategies, Challenge, and Perspectives

Recent advances in antibody-drug conjugates for breast cancer treatment.

Research Advancement in the 41st San Antonio Breast Cancer Symposium

Updates in Treatment of HER2-positive Metastatic Breast Cancer

A New Strategy for the Treatment of Heavily Pretreated Metastatic Breast Cancer: A Case Report and Review of the Literature

Recent Perspectives of Management of Breast Cancer Metastasis - an Update.

Breast Cancer: Recent Advances in Molecular Approaches

Chemotherapy strategy for metastatic breast cancer

Advances of nanomedicines in breast cancer metastasis treatment targeting different metastatic stages